Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE)‘s stock had its “overweight” rating reiterated by equities research analysts at Cantor Fitzgerald in a research note issued to investors on Tuesday. They presently have a $28.00 price objective on the stock. Cantor Fitzgerald’s price objective would suggest a potential upside of 346.57% from the company’s previous close.

ZYNE has been the subject of a number of other reports. Roth Capital set a $30.00 price target on Zynerba Pharmaceuticals and gave the stock a “buy” rating in a report on Saturday, May 13th. Canaccord Genuity set a $35.00 price target on Zynerba Pharmaceuticals and gave the stock a “buy” rating in a report on Saturday, May 13th. Maxim Group set a $32.00 price target on Zynerba Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, June 26th. Zacks Investment Research raised Zynerba Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, July 13th. Finally, BidaskClub raised Zynerba Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, July 12th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and four have issued a buy rating to the company. Zynerba Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $20.11.

Shares of Zynerba Pharmaceuticals (NASDAQ ZYNE) traded down 6.00% during midday trading on Tuesday, hitting $6.27. The company had a trading volume of 1,681,368 shares. The company has a 50-day moving average of $17.54 and a 200 day moving average of $19.50. The firm’s market capitalization is $83.12 million. Zynerba Pharmaceuticals has a 12 month low of $6.18 and a 12 month high of $25.95. Zynerba Pharmaceuticals also was the recipient of unusually large options trading on Monday. Stock traders bought 7,953 put options on the stock. This is an increase of 726% compared to the average daily volume of 963 put options.

Zynerba Pharmaceuticals (NASDAQ:ZYNE) last released its earnings results on Tuesday, August 1st. The company reported ($0.64) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.60) by $0.04. On average, analysts expect that Zynerba Pharmaceuticals will post ($2.46) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This report was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this report on another publication, it was illegally copied and republished in violation of U.S. and international trademark and copyright laws. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/08/08/cantor-fitzgerald-reiterates-overweight-rating-for-zynerba-pharmaceuticals-inc-zyne.html.

In other news, CFO James E. Fickenscher bought 5,200 shares of Zynerba Pharmaceuticals stock in a transaction dated Friday, May 12th. The stock was acquired at an average cost of $19.82 per share, with a total value of $103,064.00. Following the acquisition, the chief financial officer now owns 12,200 shares of the company’s stock, valued at $241,804. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Chairman Armando Anido bought 5,000 shares of Zynerba Pharmaceuticals stock in a transaction dated Monday, May 15th. The stock was purchased at an average cost of $19.70 per share, with a total value of $98,500.00. Following the completion of the acquisition, the chairman now directly owns 336,012 shares in the company, valued at approximately $6,619,436.40. The disclosure for this purchase can be found here. 10.02% of the stock is owned by insiders.

Hedge funds have recently bought and sold shares of the stock. Chartwell Investment Partners LLC increased its stake in Zynerba Pharmaceuticals by 19.9% in the second quarter. Chartwell Investment Partners LLC now owns 90,378 shares of the company’s stock valued at $1,534,000 after buying an additional 14,978 shares during the last quarter. Bank of New York Mellon Corp increased its stake in Zynerba Pharmaceuticals by 192.1% in the second quarter. Bank of New York Mellon Corp now owns 35,529 shares of the company’s stock valued at $602,000 after buying an additional 23,364 shares during the last quarter. Rhumbline Advisers purchased a new stake in Zynerba Pharmaceuticals during the second quarter valued at $232,000. Schwab Charles Investment Management Inc. purchased a new stake in Zynerba Pharmaceuticals during the second quarter valued at $326,000. Finally, Rothschild Investment Corp IL increased its stake in Zynerba Pharmaceuticals by 25.1% in the second quarter. Rothschild Investment Corp IL now owns 57,070 shares of the company’s stock valued at $968,000 after buying an additional 11,450 shares during the last quarter. 31.08% of the stock is owned by institutional investors and hedge funds.

Zynerba Pharmaceuticals Company Profile

Zynerba Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system.

Analyst Recommendations for Zynerba Pharmaceuticals (NASDAQ:ZYNE)

Receive News & Ratings for Zynerba Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.